Net Loss Per Share Attributable to Ordinary Shareholders

12 Months Ended

Dec. 31, 2021

Net Loss Per Share Attributable to Ordinary Shareholders

Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders

Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.

The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:

	Year ended		Year ended
	December 31		December 31
	2021		2020
	In USD thousands, except share and per share data
Numerator:
Net loss		12,478		5,951

Denominator:
Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted		207,468,650		136,755,498

Net loss per share attributable to ordinary shareholders, basic and diluted		0.060		0.044

F - 24

Chemomab Therapeutics Ltd. and its subsidiaries

Notes to the Financial Statements as at December 31, 2021

Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders (cont'd)

The potential number of weighted-average ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:

	Year ended		Year ended
	December 31		December 31
	2021		2020
	Number of shares
Outstanding options to purchase ordinary shares		27,003,260		10,455,580